mHSPC

15 drugs in development·5 companies·1 clinical trial

Drug Pipeline by Phase

Phase 3(1)

Drug	Company
Darolutamide plus ADT treatment	Royalty Pharma plc (RPRX)

Phase 2(1)

Drug	Company
Darolutamide	Novartis AG (NVS)

Phase 1(2)

Drug	Company
abiraterone	AMGEN INC (AMGN)
xaluritamig	AMGEN INC (AMGN)

Preclinical(1)

Drug	Company
pnt2001	POINT Biopharma Global Inc. (PNT)

Phase 1/Phase 2(4)

Phase 4(6)

Drug	Company
Androgen-deprivation Therapy	KYNTRA BIO INC. (KYNB)
Bridging Therapy	KYNTRA BIO INC. (KYNB)
Enzalutamide Soft Capsules	KYNTRA BIO INC. (KYNB)
Intense androgen deprivation therapy	KYNTRA BIO INC. (KYNB)
Rezvilutamide Tablets	KYNTRA BIO INC. (KYNB)
Standard Endocrine Therapy	KYNTRA BIO INC. (KYNB)

BioSniper tracks 15 drugs in development for mHSPC across 5 companies.

There are 1 clinical trial targeting mHSPC tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.